Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nebulised heparin as a treatment for lung diseases: formulation challenges and pulmonary drug delivery strategies.

Lung·2026
Same author

IL-1β Pathway Inhibition in Asthma and COPD: Strong Biological Rationale, Disappointing Clinical Trials, and Emerging New Opportunities.

Lung·2026
Same author

The Platelet/Megakaryocyte Axis is Necessary for Allergic Sensitisation and Inflammatory Responses to House Dust Mite in the Lung.

Lung·2026
Same author

The Effect of the Novel Macrolide Glasmacinal (EP395) on Allergen-Induced Eosinophil Infiltration into the Lung.

Lung·2026
Same author

Platelet-specific P2Y<sub>1</sub> receptor deficient mice have suppressed pulmonary leukocyte recruitment in response to lipopolysaccharide.

Respiratory research·2026
Same author

Pseudomonas aeruginosa infection exacerbates elastase induced lung damage: characterisation of a novel murine two-hit model of pulmonary infection.

Respiratory research·2025

Related Experiment Video

Updated: May 14, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

β2-agonist therapy in lung disease.

Mario Cazzola1, Clive P Page, Paola Rogliani

  • 1Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, Rome, Italy. mario.cazzola@uniroma2.it

American Journal of Respiratory and Critical Care Medicine
|January 26, 2013
PubMed
Summary

Beta2-agonists relax airway smooth muscle for bronchodilation. While effective, long-acting beta2-agonists carry potential risks and side effects like receptor desensitization.

More Related Videos

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
07:10

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

Generation of Human 3D Lung Tissue Cultures (3D-LTCs) for Disease Modeling
05:47

Generation of Human 3D Lung Tissue Cultures (3D-LTCs) for Disease Modeling

Published on: February 12, 2019

Related Experiment Videos

Last Updated: May 14, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
07:10

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

Generation of Human 3D Lung Tissue Cultures (3D-LTCs) for Disease Modeling
05:47

Generation of Human 3D Lung Tissue Cultures (3D-LTCs) for Disease Modeling

Published on: February 12, 2019

Area of Science:

  • Pharmacology
  • Respiratory Medicine

Background:

  • Beta2-agonists are key bronchodilators that relax airway smooth muscle (ASM) by activating beta2-adrenoceptors.
  • Short-acting beta2-agonists offer rapid symptom relief, while long-acting agents improve lung function and offer sustained benefits.

Purpose of the Study:

  • To review the mechanisms, clinical applications, and safety profiles of various beta2-agonists.
  • To discuss the evolution of beta2-agonists from short-acting to once-daily formulations.
  • To highlight ongoing developments in beta2-agonist research.

Main Methods:

  • Literature review of beta2-agonist pharmacology and clinical trials.
  • Analysis of drug mechanisms, efficacy, and safety data.
  • Discussion of receptor desensitization and tolerance phenomena.

Main Results:

  • Beta2-agonists effectively relax ASM, with varying durations of action.
  • Long-acting beta2-agonists provide sustained bronchodilation but raise safety concerns, including potential asthma mortality risks.
  • Adverse effects like increased heart rate and tremor can occur but may resolve due to receptor desensitization.

Conclusions:

  • Beta2-agonists are essential for managing obstructive airway diseases.
  • Development focuses on once-daily dosing and combination therapies to optimize efficacy and safety.
  • Further research is needed to fully understand the long-term safety of long-acting beta2-agonists.